Mallinckrodt to sell Therakos unit to CVC Capital for $925 mln

Drugmaker Mallinckrodt said on Monday it will sell its Therakos business to CVC Capital Partners (CVC.AS) for $925 million.
Dublin-based Mallinckrodt, which bought the business in 2015 for $1.33 billion, said it will use the proceeds from the deal with CVC to reduce its debt by more than 50%.